The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
New RNS out today West African nation buy initial order of 400 AIS Identifier VMS Transceiver units. Does anyone know what sort of revenue this would bring in out of interest? RNS ended with this quote so am hopeful of an extension in the future. Seems some nations need a coupl of years of seeing the product in action! " We are delighted to receive this order into a market that we have been following and advising for some years and look forward to working with our partners and authorities to increase deployments significantly in the future."
okay my last post of the day i promise. 1. we got the deal we shared the same non-exec chairman. "The Agreement is a related party transaction under the AIM Rules for Companies as Futura and Quantum share the same Non-Executive Chairman, John Clarke. The Directors of Futura, with the exception of Mr. Clarke who has taken no part in the negotiation of the Agreement other than to effect the introduction between the parties to it, consider that, having consulted with Futura's nominated adviser, that the terms of the Agreement are fair and reasonable insofar as its shareholders are concerned." http://www.futuramedical.com/content/news/archive15/141015.asp 2. we assisted in development. will this help us when licenced? Quantum Pharmaceutical is the leading manufacturer and supplier of specials and special obtains to retail pharmacies and wholesalers in the UK. Quantum's significant experience within the specials marketplace enabled the Company to work with Futura to develop manufacturing processes, testing methods, product development and production scalability to allow MED2002 to be made available as a special. http://ir.quantumpharmagroup.com/content/news/news_archive/2015/14-10-15.asp i am still weighing up what this all means for us. further comments from the usual suspects on here most welcome.
okay my last post of the day i promise. 1. we got the deal we shared the same non-exec chairman. "The Agreement is a related party transaction under the AIM Rules for Companies as Futura and Quantum share the same Non-Executive Chairman, John Clarke. The Directors of Futura, with the exception of Mr. Clarke who has taken no part in the negotiation of the Agreement other than to effect the introduction between the parties to it, consider that, having consulted with Futura's nominated adviser, that the terms of the Agreement are fair and reasonable insofar as its shareholders are concerned." http://www.futuramedical.com/content/news/archive15/141015.asp 2. we assisted in development. will this help us when licenced? Quantum Pharmaceutical is the leading manufacturer and supplier of specials and special obtains to retail pharmacies and wholesalers in the UK. Quantum's significant experience within the specials marketplace enabled the Company to work with Futura to develop manufacturing processes, testing methods, product development and production scalability to allow MED2002 to be made available as a special. http://ir.quantumpharmagroup.com/content/news/news_archive/2015/14-10-15.asp i am still weighing up what this all means for us. further comments from the usual suspects on here most welcome.
jjst found the below on this link. http://www.futuramedical.com/content/products/med_2002.asp "We have out-licensed exclusive rights to Quantum Pharma plc for the manufacture and supply of MED2002 as an unlicensed medicine ("Special") in the UK. Quantum is the leading manufacturer and supplier of Specials to retail pharmacies and wholesalers in the UK. In return, Futura will receive undisclosed royalty payments from Quantum on the sale of the product." does this mean we will only have rights as an unlicenced product then? when licenced we will need another deal? or perhaps they could market it on their own?
Interesting RNS today http://uk.advfn.com/stock-market/london/galantas-gold-GAL/share-news/Galantas-Gold-Corporation-Galantas-targets-early-o/72372429 We should have less financing to raise possibly if we have some easy win gold for mining
well i did not see such a strong bounce back on the cards. to be honest i thought there would be a huge bounce back after the Q3 numbers if the ARPU showed itself in that update. could be PLUS buying back their own stock?
half year results show we are really motoring now on converting acquisions in earnings enhancements as well as organic growth. well positioned to push on from here no doubt! HIGHLIGHTS * Strong performance with Adjusted Operating Profit(1) increasing by 42.5% to GBP16.1 million * Adjusted Profit Before Tax(2) up by 39.6% to GBP14.1 million * Interim dividend of 0.80 pence per share, up 23.1% * Textile Rental continues to perform strongly * Acquisitions performing ahead of management expectations and significantly increasing our presence in the high volume hotel linen market * Successful placing of 33.1 million new shares, raising net proceeds of GBP28.7 million * Net debt slightly better than expected at GBP108.9 million (Pro-forma(4) December 2015: GBP115.6 million) * Amended Bank Facility signed in April 2016 providing significant headroom for future investment
Pidlan, did you read the whole thing? It's a jam tomorrow situation. Earnings are a little down as customer acquisition was higher than expected. As customer acquisition cost is expensed up front and revs from said customers are only booked as they earn it. They have actually signed up more than they anticipated and are nearly at full year new customer target. Also stated these new customers are high value. I am pretty pleased with progress as they said without extraordinary new customer expense, margin would be around 50%!! The full year will obviously give the complete picture but Q3 update will give us a flavour.
the more i think about it the more i am convinced of strong results. re: village idiot --> i have filtered him out! I have heard too many of his rants. IF he has genuine issues this is not the forum to repeatedly shout about it.
Hi monkey, thanks for your inputs much appreciated. below i assume ebitda margin of 45% and revenues in Q2 to be 75% of what we achieved in Q1. That is the same ratio as 2014, 2015 results disturbed with reg mishap. so as you say if ebitda margin or revenues beat these numbers we should have some positive momentum revs in Q1 = $85m. revs in q2 = $64m. (75% of q1 revs, this is ratio from 2014). therefore H1 revs estimated = $148m. ebitda = 66.6m (assuming 45%) shares in issues 114,890,000. EPS = 58 cents. Div (if 60% payout ratio held which is likely) = 35cents. Div in pence = 27p FOR THE HALF YEAR ONLY
Hi All, Bgw. I have been doing some calc ahead of the iterims. can you let me know if you agree or i have made an incorrect assumption somewhere? revs in Q1 = $85m. revs in q2 = unknown but assume $85m again. therefore H1 revs estimated = $170m. ebitda (has been around 50% of revs in previous updates) = $85m. shares in issues 114,890,000. EPS = 78cents. Div (if 60% payout ratio held which is likely) = 47cents. Div in pence = 38p FOR THE HALF YEAR ONLY
me too robins. but as they mention sales will be second half weighted. when they say "expect the Group to meet market expectations for the full year to 31 January 2017" . . . .where can we get hold of market expectations? what exactly are they referring to? broker notes on them?
Sonofelvis, I agree the figures you suggest below look on the mark assuming all goes smoothly with no hiccups. So many things have gone their way. Some fortuatous like the excahnge rate and some from their smart management and great business plan. I am not negative on their outlook at all i just wanted to get across how hard it is for estimates to be made. Indeed if we actually saw a poor update as cases had not closed during the period we would probably have a huge update the one after that. I would see it as a buying opportunity (again). in the short term would be nice to base ourselves above 400p!
Robins this is the ultimate stock that needs patience!! Price has had a run up, broken through 80p which I think is significant for momentum too. Think it's a case of sitting on our hands until all those things you mention start to get delivered/resolved.